Denali Therapeutics Inc. (DNLI)

NASDAQ: DNLI · Real-Time Price · USD

24.42

+0.25 (1.03%)

Aug 5, 2026, 4:00 PM EDT - Market closed

Denali Therapeutics Financials Overview

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	-	-	-	330.53	-	-
Revenue Growth	-	-	-	-	-	-
Gross Profit	-	-	-	330.53	-	-
Operating Income	-547.12	-555.34	-487.34	-196.7	-340.74	-295.75
Net Income	-508.02	-512.54	-422.77	-145.22	-325.99	-290.58
Earnings Per Share	-2.88	-2.97	-2.57	-1.06	-2.60	-2.39
EPS Growth	-	-	-	-	-	-

Revenue by Segment

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep '23 Sep 30, 2023	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Takeda Collaboration	-	10	51.92	29.92	27.16	5.93
Sanofi Collaboration	-	25	53.4	15	1.07	20.75
Biogen Collaboration	295.79	295.53	3.15	3.74	307.44	-
Revenue (Total)	-	330.53	-	-	-	-

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	987.68	867.88	832.33	1,035	1,336	865.41
Total Debt	30.19	32.74	42.29	44.98	53.03	58.55
Net Cash (Debt)	957.5	835.14	790.04	989.53	1,283	806.85
Net Cash Growth	24.46%	5.71%	-20.16%	-22.88%	59.04%	-42.59%
Net Cash Per Share	5.43	4.84	4.80	7.20	10.22	6.64

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	-412.34	-412.6	-347.69	-357.99	-244.72	-211.39
Capital Expenditures	-6.89	-9.5	-15.91	-12.94	-17.83	-8.5
Free Cash Flow	-419.23	-422.1	-363.61	-370.93	-262.55	-219.89
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	-	-	-	100.00%	-	-
Operating Margin	-	-	-	-59.51%	-	-
Pretax Margin	-	-	-	-43.93%	-	-
Profit Margin	-	-	-	-43.94%	-	-
FCF Margin	-	-	-	-112.22%	-	-

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 6, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Forward PE	-	46.46	46.46	46.46	46.46	46.46
PS Ratio	-	-	-	8.98	-	-